Some patients taking GLP-1 weight loss drugs like Ozempic are reporting changes in their emotions and personality, and doctors are beginning to take notice, according to a report by TODAY.com.
The phenomenon has been given an informal name: "Ozempic personality." Patients and clinicians have used the term to describe a range of reported changes, including emotional blunting, reduced motivation, and a flattening of feelings that users say emerged after they began taking the medication.
GLP-1 receptor agonists, which include semaglutide sold under brand names like Ozempic and Wegovy, were originally developed to treat type 2 diabetes and have more recently been widely prescribed and used for weight loss. The drugs work by mimicking a hormone that targets areas of the brain involved in appetite regulation, which leads to reduced hunger and, for many users, significant weight loss.
The concern being raised now is whether those same brain pathways involved in appetite and reward may also influence mood, motivation, and emotional response. Some patients have described feeling less joy in activities they previously enjoyed, alongside the reduced cravings for food that the drugs are intended to produce.
Doctors interviewed for the TODAY.com report have said the experiences patients are describing are worth taking seriously, though the picture is not straightforward. Weight loss itself can change mood and personality, and distinguishing between effects caused by the drug and effects caused by changes in body weight or diet is difficult. Some patients report feeling better emotionally after losing weight on the medication, while others describe the blunting effect as unwanted and concerning.
The question of how GLP-1 drugs affect the brain beyond appetite regulation is an area of active interest. Researchers have been looking at whether these medications may have broader neurological effects, given that GLP-1 receptors exist in parts of the brain associated not just with hunger but with reward and emotion.
For patients currently taking these medications, the reports add to a growing list of considerations beyond the well-documented physical side effects such as nausea, vomiting, and gastrointestinal discomfort. Whether a formal clinical link between GLP-1 drugs and emotional changes will be established through research remains an open question, and patients experiencing mood changes are encouraged by physicians to discuss those changes with their prescribing doctor.
The widespread use of these medications, which has expanded rapidly over the past few years, means that even relatively uncommon side effects could affect a large number of people. The informal label of "Ozempic personality" may not be a clinical diagnosis, but the reports behind it are drawing enough attention from both patients and the medical community to make it a subject of ongoing discussion.
